MRI correlates of disability progression in patients with CIS over 48 months
暂无分享,去创建一个
Robert Zivadinov | Niels Bergsland | Dana Horakova | D. Ramasamy | R. Zivadinov | E. Havrdová | N. Bergsland | D. Horáková | T. Uher | J. Krasensky | M. Vaněčková | M. Týblová | Z. Seidl | Deepa P. Ramasamy | Eva Havrdova | Michaela Tyblova | Tomas Uher | Manuela Vaneckova | Zdenek Seidl | Jan Krasensky
[1] Elizabeth Fisher,et al. Brain atrophy and magnetization transfer ratio following methylprednisolone in multiple sclerosis: short-term changes and long-term implications , 2005, Multiple sclerosis.
[2] J. LERE BOULLET,et al. [Brain atrophy]. , 1954, La Revue du praticien.
[3] R. Zivadinov,et al. Advances in understanding gray matter pathology in multiple sclerosis: Are we ready to redefine disease pathogenesis? , 2012, BMC Neurology.
[4] M. Battaglini,et al. Cortical lesions in radiologically isolated syndrome , 2011, Neurology.
[5] R. Henry,et al. Regional grey matter atrophy in clinically isolated syndromes at presentation , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.
[6] M. Dwyer,et al. Cine cerebrospinal fluid imaging in multiple sclerosis , 2012, Journal of magnetic resonance imaging : JMRI.
[7] E. Portaccio,et al. Evidence for relative cortical sparing in benign multiple sclerosis: a longitudinal magnetic resonance imaging study , 2009, Multiple sclerosis.
[8] Turi O. Dalaker,et al. Brain atrophy and disability progression in multiple sclerosis patients: a 10-year follow-up study , 2014, Journal of Neurology, Neurosurgery & Psychiatry.
[9] Jeffrey A. Cohen,et al. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria , 2011, Annals of neurology.
[10] À. Rovira,et al. Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes , 2013, Multiple sclerosis.
[11] M. Ramanathan,et al. Interactions of serum cholesterol with anti-herpesvirus responses affect disease progression in clinically isolated syndromes , 2013, Journal of Neuroimmunology.
[12] Robert Zivadinov,et al. Improved longitudinal gray and white matter atrophy assessment via application of a 4-dimensional hidden Markov random field model , 2014, NeuroImage.
[13] C. Poser,et al. Diagnostic criteria for multiple sclerosis , 2001, Clinical Neurology and Neurosurgery.
[14] M. Ramanathan,et al. Environmental Factors Associated with Disease Progression after the First Demyelinating Event: Results from the Multi-Center SET Study , 2013, PloS one.
[15] M. Ramanathan,et al. Lipid pro fi les are associated with lesion formation over 24 months in interferon-β treated patients following the fi rst demyelinating event , 2013 .
[16] Ondrej Dolezal,et al. Clinical correlates of grey matter pathology in multiple sclerosis , 2012, BMC Neurology.
[17] Bertrand Audoin,et al. Prevalence of Grey Matter Pathology in Early Multiple Sclerosis Assessed by Magnetization Transfer Ratio Imaging , 2011, PloS one.
[18] S. Reingold,et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” , 2005, Annals of neurology.
[19] Dana Horakova,et al. Volumetric MRI Markers and Predictors of Disease Activity in Early Multiple Sclerosis: A Longitudinal Cohort Study , 2012, PloS one.
[20] David H. Miller,et al. Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. , 2004, Brain : a journal of neurology.
[21] J H Simon,et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. , 2000, The New England journal of medicine.
[22] Chiara Romualdi,et al. Cortical atrophy is relevant in multiple sclerosis at clinical onset , 2007, Journal of Neurology.
[23] J. Ranjeva,et al. Atrophy mainly affects the limbic system and the deep grey matter at the first stage of multiple sclerosis , 2010, Journal of Neurology, Neurosurgery & Psychiatry.
[24] J. L. Cox,et al. Evolution of different MRI measures in patients with active relapsing-remitting multiple sclerosis over 2 and 5 years: a case–control study , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.
[25] Simon Hametner,et al. Disease-specific molecular events in cortical multiple sclerosis lesions , 2013, Brain : a journal of neurology.
[26] M. Dwyer,et al. Thalamic atrophy is associated with development of clinically definite multiple sclerosis. , 2013, Radiology.
[27] Peter K. Stys,et al. Gray matter pathology in (chronic) MS: Modern views on an early observation , 2009, Journal of the Neurological Sciences.
[28] G. Comi,et al. Freedom from disease activity in multiple sclerosis , 2010, Neurology.
[29] J. Ranjeva,et al. Individual voxel‐based analysis of brain magnetization transfer maps shows great variability of gray matter injury in the first stage of multiple sclerosis , 2010, Journal of magnetic resonance imaging : JMRI.
[30] B. Healy,et al. Assessment of Definitions of Sustained Disease Progression in Relapsing-Remitting Multiple Sclerosis , 2013, Multiple sclerosis international.
[31] M. Dwyer,et al. Subcortical and Cortical Gray Matter Atrophy in a Large Sample of Patients with Clinically Isolated Syndrome and Early Relapsing-Remitting Multiple Sclerosis , 2012, American Journal of Neuroradiology.
[32] C. Guttmann,et al. Multiple sclerosis susceptibility loci do not alter clinical and MRI outcomes in clinically isolated syndrome , 2013, Genes and Immunity.
[33] R. Rudick,et al. Gray matter atrophy in multiple sclerosis: A longitudinal study , 2008, Annals of neurology.
[34] T. Winder. Lipid profiles. , 1994, British journal of hospital medicine.
[35] M. Calabrese,et al. Cortical lesion load associates with progression of disability in multiple sclerosis. , 2012, Brain : a journal of neurology.
[36] Marco Bozzali,et al. Gray- and white-matter changes 1 year after first clinical episode of multiple sclerosis: MR imaging. , 2010, Radiology.
[37] C. Lucchinetti,et al. Meningeal and cortical grey matter pathology in multiple sclerosis , 2012, BMC Neurology.
[38] J Sastre-Garriga,et al. Clinical impact of early brain atrophy in clinically isolated syndromes , 2013, Multiple sclerosis.
[39] M. Calabrese,et al. The predictive value of gray matter atrophy in clinically isolated syndromes , 2011, Neurology.
[40] S. Hussein,et al. Evolution of Cortical and Thalamus Atrophy and Disability Progression in Early Relapsing-Remitting MS during 5 Years , 2013, American Journal of Neuroradiology.
[41] P. Matthews,et al. Normalized Accurate Measurement of Longitudinal Brain Change , 2001, Journal of computer assisted tomography.
[42] E. Radue,et al. Rate of brain atrophy in relapsing MS decreases during treatment with IFNβ-1a , 2005, Neurology.
[43] M. Filippi,et al. Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis , 2008, Neurology.
[44] Massimo Filippi,et al. A voxel-based morphometry study of grey matter loss in MS patients with different clinical phenotypes , 2008, NeuroImage.
[45] M. Ramanathan,et al. Lipid profiles are associated with lesion formation over 24 months in interferon-β treated patients following the first demyelinating event , 2013, Journal of Neurology, Neurosurgery & Psychiatry.
[46] M. Calabrese,et al. Low degree of cortical pathology is associated with benign course of multiple sclerosis , 2013, Multiple sclerosis.
[47] F. Barkhof,et al. A three-year, multi-parametric MRI study in patients at presentation with CIS , 2008, Journal of Neurology.
[48] M. Battaglini,et al. Improving the Characterization of Radiologically Isolated Syndrome Suggestive of Multiple Sclerosis , 2011, PloS one.
[49] P. Matthews,et al. Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disability , 2011, Multiple sclerosis.
[50] Stephen M. Smith,et al. A Bayesian model of shape and appearance for subcortical brain segmentation , 2011, NeuroImage.